Case Report

Plasma Exchange in the Management of Catastrophic Antiphospholipid Syndrome

Dimitri Titeca-Beauport,1,2 Valery Salle,3 Loay Kontar,1 Julien Maizel,1 and Gabriel Choukroun2

1Medical Intensive Care Unit, Amiens University Medical Center, Amiens, France
2Nephrology, Dialysis and Transplantation Department, Amiens University Medical Center, Amiens, France
3Department of Internal Medicine, Amiens University Medical Center, Amiens, France

Correspondence should be addressed to Dimitri Titeca-Beauport; titeca.dimitri@chu-amiens.fr

Received 11 August 2016; Accepted 20 September 2016

Objective. Report of a case of catastrophic antiphospholipid syndrome (CAPS) with multiple organ involvement leading to a life-threatening condition despite early combination corticosteroid and heparin therapy. Initiation of plasma exchange led to rapid improvement of the patient’s general condition.

Design. Case report.

Setting. University teaching hospital medical intensive care unit.

Patient. Single case: 52-year-old man hospitalized for catastrophic antiphospholipid syndrome (CAPS) with cardiac, renal, and cutaneous involvement. Despite early methylprednisolone and heparin therapy, the patient’s condition progressively deteriorated, resulting in acute renal failure, right adrenal hemorrhage, and pulmonary involvement, leading to acute respiratory distress on day 6, requiring high-flow nasal cannula oxygen therapy with FiO2 of 1.0.

Interventions. Plasma exchange was started on day 6.

Endpoints and Main Results. A marked improvement of the patient’s general condition was observed after initiation of plasma exchange, with successful weaning of oxygen therapy and normalization of platelet count, troponin, and serum creatinine within four days.

Conclusions. This case illustrates the efficacy of plasma exchange in CAPS and the difficulty for physicians to determine the optimal timing of plasma exchange.

1. Introduction

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by a combination of arterial and/or venous thrombosis, obstetric complications, and antiphospholipid antibodies (aPL). The clinical features of APS can range from moderate symptoms to a life-threatening variant called catastrophic antiphospholipid syndrome (CAPS), first described by Asherson in 1992 [1]. CAPS is defined by the involvement of at least three different organ systems over a period of days or weeks and laboratory confirmation of the presence of anti-phospholipid antibodies (aPL) such as anti-β2-glycoprotein-I (aβ2GPI) and anti-cardiolipin antibodies (aCL) [2].

2. Case Report

We report the case of a 52-year-old man with primary antiphospholipid syndrome (APS) for twelve years, with one episode of deep vein thrombosis, migraine, and persistent high titers of IgG anti-cardiolipin and aβ2GPI antibodies.

Three weeks before admission to hospital, the patient presented an episode of acute bacterial prostatitis treated by ciprofloxacin for 2 weeks.

On the day of admission, he presented deterioration of his general condition, with weight loss, splinter hemorrhages, leg ulcers, and livedo reticularis.

Electrocardiography (ECG) revealed ST-segment depression in the lateral territory. Echocardiography showed left ventricular dysfunction with an ejection fraction between 30 and 35% but no regional wall motion abnormalities.

Laboratory results showed elevated cardiac troponin at 16.3 μg/L, thrombocytopenia with a platelet count of 76 x 10^3/mm^3, no schizocytes, elevated C-reactive protein of 94 mg/L, prothrombin time within the therapeutic range (INR: 4.35), microscopic hematuria without renal failure, and...
On day 11, the patient was discharged from the intensive care unit to the medical ward, where plasma exchange was gradually performed less frequently.

3. Discussion

This case illustrates the difficulty for the clinicians to evaluate the optimal timing for initiation of PE in patients with CAPS. Patients with CAPS represent less than 1% of all patients with APS, but CAPS constitutes the first manifestation of APS in approximately one-half of cases. More than one-third of cases of CAPS are triggered by acute infection [3]. This syndrome is also characterized by higher plasmatic ferritin concentration compared to patients with classic APS, which could contribute to the “cytokine storm,” leading to multiple organ dysfunction [4]. In this regard, some authors proposed to include CAPS in a common syndrome entity termed “Hyperferritinemia Syndrome” including macrophage activation syndrome, adult onset Still’s disease, and septic shock [5].

CAPS is a life-threatening condition that usually requires admission to the ICU [6]. In a published series of 250 cases from 1992 to 2005, the mortality rate was 48%. Cerebral complications, cardiac complications, and infections were the main causes of death. The only independent poor prognostic factor was the association with systemic lupus erythematosus (SLE). In this series, the most commonly reported treatment combination was anticoagulants (AC) plus corticosteroids (CS) with a recovery rate of only 63.8%. The highest recovery rate (77.8%) was achieved with a combination of AC + CS + PE, followed by AC + CS + PE and/or IVIG (69%) [5]. Since 2001, the increased use of AC + CS + PE and/or IVIG has resulted in a 20% reduction of mortality, with a current mortality rate of 39% [3, 7]. In a series of 230 cases of CAPS, treatment with PE was independently associated with decreased mortality [OR 0.36 (0.14–0.92) p = 0.033] [6]. PE therefore appears to be the most effective treatment for CAPS, probably through prompt removal of circulating antiphospholipid antibodies [8–10]. We may also consider that PE could remove proinflammatory mediators such as serum ferritin, TNF-α, IL-1, IL-6, and IL-18 [5].

The place of immunosuppressant therapy in CAPS has not been clearly defined. Cyclophosphamide was used in one-third of cases but has only been shown to be beneficial in the case of SLE flare [8]. Rituximab appeared to be beneficial in a series of twenty cases with a recovery rate of 75% and Eculizumab use has been reported in some refractory cases of CAPS [11].

In this case of CAPS with multiorgan involvement, PE was delayed due to the initial absence of any clinical signs of severity. Despite corticosteroid and unfractionated heparin therapy, the patient’s general condition progressively deteriorated until initiation of PE.

Guidelines from international consensus statements recommend initiation of PE in the case of life-threatening forms of CAPS (especially in the presence of schizocytes) [12]. On the other hand, only 30% of more than 400 cases reported by the CAPS registry received PE [3]. PE therefore does not...
appear to be always necessary in patients with CAPS. More prognostic factors must be defined to help clinicians identify those patients who will require early initiation of PE.

The major challenge therefore consists of identifying those patients likely to benefit from this therapy and determining the optimal timing of initiation of PE. Monitoring of laboratory parameters, such as increased aPL titers, troponin, serum creatinine, and decreased platelet count can contribute to evaluation of the efficacy of treatment and decision-making. In the case reported here, PE was rapidly effective, probably because of the high aPL titers [13].

4. Conclusion

CAPS is an uncommon but potentially life-threatening condition. In view of the lack of clinical trials, optimal management remains unknown, but a combination of AC + CS + PE and/or IVIG appears to be the most effective treatment option. This case illustrates the difficulty for physicians to determine the optimal timing of plasma exchange. A better understanding of the pathophysiology and a more precise description of clinical and laboratory characteristics could help clinicians identify those patients who may benefit from early initiation of PE.

Competing Interests

The authors declare no competing interests.

References

[1] R. A. Asherson, "The catastrophic antiphospholipid syndrome," Journal of Rheumatology, vol. 19, no. 4, pp. 508–512, 1992.

[2] N. Costedoat-Chalumeau, L. Arnaud, D. Saadoun et al., "Catastrophic antiphospholipid syndrome," La Revue de Médecine Interne, vol. 33, no. 4, pp. 194–199, 2012.

[3] CAPS Registry, Registry of the "European forum on antiphospholipid antibodies" for patients with the "catastrophic" antiphospholipid syndrome, https://ontocfr.grupocostaisa.com/es/web/caps/statisticsjsessionid.

[4] N. Agmon-Levin, C. Rosário, B.-S. P. Katz et al., “Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS),” Lupus, vol. 22, no. 13, pp. 1327–1335, 2013.

[5] C. Rosário, G. Zandman-Goddard, E. G. Meyron-Holtz, D. P. D'Cruz, and Y. Shoenfeld, "The Hyperferritinemic Syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome," BMC Medicine, vol. 11, no. 1, article 185, 2013.

[6] G. E. Westney and E. N. Harris, "Catastrophic antiphospholipid syndrome in the intensive care unit," Critical Care Clinics, vol. 18, no. 4, pp. 805–817, 2002.

[7] S. Bucciarelli, G. Espinosa, R. Cervera et al., “Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients,” Arthritis and Rheumatism, vol. 54, no. 8, pp. 2568–2576, 2006.

[8] U. D. Bayraktar, D. Erkan, S. Bucciarelli, G. Espinosa, and R. Asherson, “The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus,” The Journal of Rheumatology, vol. 34, no. 2, pp. 346–352, 2007.

[9] I. Uthman, A. Shamseddine, and A. Taher, "The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome," Transfusion and Apheresis Science, vol. 33, no. 1, pp. 11–17, 2005.

[10] M. Bortolati, P. Marson, F. Fabris et al., "Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: report of four cases and review of the literature," Autoimmunity Reviews, vol. 8, no. 4, pp. 297–301, 2009.

[11] N. M. Kazzaz, W. J. McCune, and J. S. Knight, "Treatment of catastrophic antiphospholipid syndrome," Current Opinion in Rheumatology, vol. 28, no. 3, pp. 218–227, 2016.

[12] R. A. Asherson, R. Cervera, P. G. de Groot et al., "Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines," Lupus, vol. 12, no. 7, pp. 530–534, 2003.

[13] T. Zar and A. A. Kaplan, "Predictable removal of anticardiolipin antibody by therapeutic plasma exchange (TPE) in catastrophic antiphospholipid antibody syndrome (CAPS)," Clinical Nephrology, vol. 70, no. 1, pp. 77–81, 2008.